| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:10492900 | IVR | 3 mg/kg | 3 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 3 mg/kg | 3 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.3 mg/kg | 0.3 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | - | No significant effects observed | - | |
| PMID:10641015 | IVR | 100 - 150 mg/kg | 100 mg/kg | Alterations in preputial separation | Reproductive endocrine-mediated perturbations |
| PMID:10737536 | IVR | 500 mg/kg | 500 mg/kg | Erectile dysfunction | Reproductive endocrine-mediated perturbations |
| PMID:11934530 | IVR | 40 mg/kg/day | 40 mg/kg/day | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Uterine hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Changes in morphology of cervix | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Hyperplasia in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 40 mg/kg/day | 40 mg/kg/day | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| PMID:12460804 | IVTH | 0.000025 - 0.00005 M | 0.00005 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| PMID:16243481 | IVTH | 0.000003 M | 0.000003 M | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| PMID:17686919 | IVR | 50 mg/kg/day | 50 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 160 mg/kg/day | 160 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 160 mg/kg/day | 160 mg/kg/day | Increased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 160 mg/kg/day | 160 mg/kg/day | Increased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 160 mg/kg/day | 160 mg/kg/day | Affects amino acid metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 160 mg/kg/day | 160 mg/kg/day | Increased cowper's gland weights | Reproductive endocrine-mediated perturbations | |
| IVR | 160 mg/kg/day | 160 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 16 mg/kg/day | - | No significant effects observed | - | |
| IVR | 5 mg/kg/day | - | No significant effects observed | - | |
| PMID:19241440 | IVR | 16 mg/kg | 16 mg/kg | Decreased weights of accessory sex organs | Reproductive endocrine-mediated perturbations |
| IVR | 16 mg/kg | 16 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 160 mg/kg | 160 mg/kg | Decreased weights of accessory sex organs | Reproductive endocrine-mediated perturbations | |
| IVR | 160 mg/kg | 160 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:21512963 | IVR | 100 mg/kg | 100 mg/kg | Affects expression of thyroid receptor (TR) | Metabolic endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 60 mg/kg | 60 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 60 mg/kg | 60 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects Transthyretin (TTR) levels | Metabolic endocrine-mediated perturbations | |
| PMID:22514210 | IVR | 0.02 mg | 0.02 mg | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:25187598 | IVR | 100 mg/kg | 100 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| PMID:25682698 | IVTH | 0.000001 - 0.00001 M | 0.000001 - 0.00001 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.00001 M | 0.000001 - 0.00001 M | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| PMID:26928317 | IVR | 35 mg/kg | 35 mg/kg | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations |
| PMID:28572628 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects cytokine signaling | Immunological endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:29554563 | IVR | 112.5 mg/kg/day | 112.5 mg/kg/day | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations |
| PMID:30153481 | IVR | 100 mg/kg | 100 mg/kg | Decreased testis weights in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Affects testicular function in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects spermatogenesis in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects sperm motility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Epigenomic alterations in sperm in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Changes in morphology of seminiferous tubules in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Pregnancy complications in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects fertility in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30414542 | IVTH | 0.1 mg/L | 0.1 mg/L | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.1 mg/L | 0.1 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.01 mg/L | 0.01 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.01 mg/L | 0.01 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.00001 mg/L | 0.00001 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00001 mg/L | 0.00001 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.001 mg/L | 0.001 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.001 mg/L | 0.001 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 1 mg/L | 1 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 1 mg/L | 1 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 mg/L | 0.0001 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 mg/L | 0.0001 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| PMID:30415545 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations |
| PMID:31923581 | IVTH | 0.01 mg/L | 0.01 mg/L | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.01 mg/L | 0.01 mg/L | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.001 mg/L | 0.001 mg/L | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.001 mg/L | 0.001 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0001 mg/L | - | No significant effects observed | - | |
| PMID:9168009 | IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.